Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

4basebio Plc (4BB) Share Price

Price 1,125.00p on 09-05-2025 at 18:50:05
Change 0.00p 0%
Buy 1,150.00p
Sell 1,100.00p
Buy / Sell 4BB Shares
Last Trade: Sell 18.00 at 1,100.00p
Day's Volume: 633
Last Close: 1,125.00p
Open: 1,125.00p
ISIN: GB00BMCLYF79
Day's Range 1,125.00p - 1,125.00p
52wk Range: 1,110.00p - 1,820.00p
Market Capitalisation: £174m
VWAP: 1,108.51027p
Shares in Issue: 15m

4basebio Plc (4BB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 18 1,100.00p Ordinary
14:08:53 - 09-May-25
Sell* 231 1,102.00p Ordinary
13:54:59 - 09-May-25
Sell* 20 1,100.00p Ordinary
13:53:41 - 09-May-25
Sell* 20 1,100.00p Ordinary
13:53:17 - 09-May-25
Unknown* 55 1,125.00p Ordinary
11:49:10 - 09-May-25
Unknown* 52 1,125.00p Ordinary
11:33:46 - 09-May-25
Sell* 100 1,122.50p Ordinary
08:58:29 - 09-May-25
Sell* 137 1,100.00p Ordinary
08:33:54 - 09-May-25
Buy* 350 1,131.70p Ordinary
09:13:59 - 08-May-25
Buy* 1 1,132.00p Ordinary
09:31:08 - 07-May-25
See more 4basebio Plc trades

4basebio Plc (4BB) Share Price History

Time period:
to
Date Open High Low Close Volume
9th May 2025 (Fri) 1,125.00 1,125.00 1,125.00 1,125.00 633
8th May 2025 (Thu) 1,125.00 1,125.00 1,125.00 1,125.00 350
7th May 2025 (Wed) 1,125.00 1,125.00 1,125.00 1,125.00 1
6th May 2025 (Tue) 1,125.00 1,125.00 1,125.00 1,125.00 2
5th May 2025 (Mon) 1,122.40 1,122.40 1,122.40 1,122.40 0
2nd May 2025 (Fri) 1,125.00 1,125.00 1,125.00 1,125.00 373
1st May 2025 (Thu) 1,125.00 1,125.00 1,125.00 1,125.00 674
30th Apr 2025 (Wed) 1,125.00 1,125.00 1,125.00 1,125.00 138
29th Apr 2025 (Tue) 1,125.00 1,125.00 1,125.00 1,125.00 0
28th Apr 2025 (Mon) 1,125.00 1,125.00 1,125.00 1,125.00 109
25th Apr 2025 (Fri) 1,125.00 1,125.00 1,125.00 1,125.00 693
24th Apr 2025 (Thu) 1,125.00 1,125.00 1,125.00 1,125.00 0
23rd Apr 2025 (Wed) 1,125.00 1,125.00 1,125.00 1,125.00 456
22nd Apr 2025 (Tue) 1,125.00 1,125.00 1,125.00 1,125.00 146
21st Apr 2025 (Mon) 1,125.00 1,125.00 1,125.00 1,125.00 0
18th Apr 2025 (Fri) 1,125.00 1,125.00 1,125.00 1,125.00 0
17th Apr 2025 (Thu) 1,125.00 1,125.00 1,125.00 1,125.00 0
16th Apr 2025 (Wed) 1,125.00 1,125.00 1,125.00 1,125.00 1,100
15th Apr 2025 (Tue) 1,155.00 1,155.00 1,130.00 1,130.00 2,194
14th Apr 2025 (Mon) 1,155.00 1,155.00 1,155.00 1,155.00 0
11th Apr 2025 (Fri) 1,110.00 1,175.00 1,110.00 1,155.00 2,420
See more 4basebio Plc price history

4basebio Plc (4BB) Regulatory News

Date Source Headline
4th Apr 2025 12:00 pm PRN Director Dealing
2nd Apr 2025 7:00 am PRN 4basebio Receives GMP Licence for its UK DNA Manufacturing Facility
25th Mar 2025 10:15 am PRN Holding(s) in Company
14th Mar 2025 7:00 am PRN RBC Capital Markets initiates research coverage
7th Mar 2025 7:00 am PRN Employee Long Term Incentive Plan and Issue of Equity
3rd Mar 2025 4:37 pm PRN Director's Dealing
8th Jan 2025 7:00 am PRN Appointment of Chief Commercial Officer
17th Dec 2024 7:00 am PRN Directorate Change
29th Nov 2024 12:30 pm PRN Director's Dealing
19th Nov 2024 2:15 pm PRN Director's Dealing
See more 4basebio Plc regulatory news

4basebio Plc (4BB) Share News

IN BRIEF: 4basebio hits "critical milestone" as it secures GMP licence

2nd Apr 2025 09:51

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Secures good manufacturing practice, or GMP, certification for its UK DNA manufacturing facility from the UK Medicines & Healthcare Products Regulatory Agency. This authorises it to manufacture and supply investigational medicinal product drug substance and critical starting biological medicinal materials used in advanced therapy medicinal products from its Cambridge facility, says the firm. Adds that the certification strengthens its position in the advanced therapeutics field and progresses it towards commercialisation and patient care for a range of advanced therapies. Chief Executive Heikki Lanckriet says: "Achieving GMP certification is a critical milestone for 4basebio, validates our ability to supply synthetic DNA for clinical applications and underscores the hard work and innovation of our team and sets the stage for the next phase of growth for the company." Read More

IN BRIEF: 4basebio names Gabe Longoria as new chief commercial officer

8th Jan 2025 11:47

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Names Gabe Longoria as the new chief commercial officer. Longoria was previously CCO at Astrea Bioseparations Ltd. The appointment follows a GBP40 million investment into 4basebio by Elevate Medical Technologies and M&G Investment Management Ltd, which completed in November. This is a "key milestone" for the company. Read More

IN BRIEF: 4basebio to supply synthetic DNA for mRNA vaccine program

10th Apr 2024 11:21

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Announces the supply of its HQ synthetic DNA to an unnamed "Tier 1 pharma company". Says the client will use the synthetic DNA in late preclinical studies for an mRNA vaccine program. Financial details of the contract were not provided by 4basebio. Read More

4basebio updates markets on "key milestone" with client

21st Mar 2024 14:09

(Alliance News) - 4basebio PLC on Thursday noted a "key milestone" with its client, which is progressing into a phase one clinical trial. Read More

TRADING UPDATES: Alpha Real Trust says in "robust" financial shape

1st Mar 2024 18:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

See more 4basebio Plc news
FTSE 100 Latest
Value8,554.80
Change23.19

Login to your account

Forgot Password?

Not Registered